PEP-0038Research chemical

GHRP-2

Also known as

GHRP-2 is catalogued in the Peptides Pub research index, with coverage focused on Lean mass.

Evidence

Limited· 4.8

Small or single human study

Risk band

Elevated

Serious AEs reported or theoretical

Research goals

Lean mass

Summary

GHRP-2 (pralmorelin) is a synthetic growth hormone-releasing peptide and GHS-R agonist developed primarily as a diagnostic agent for hypothalamic-pituitary function; it was awaiting approval in Japan for this diagnostic indication and underwent phase II trials for short stature, while US development for GH deficiency was discontinued [1]. In a controlled human study, GHRP-2 infusion increased food intake by roughly 36% versus saline in healthy men and significantly raised serum GH levels, paralleling effects reported for ghrelin [2]. Preclinical work indicates GHRP-2 can directly act on myocytes to attenuate muscle-atrophy-related ubiquitin ligases [4]. The remaining literature concerns urinary detection of GHRP-2 in anti-doping testing rather than therapeutic efficacy [3]. Human evidence for GHRP-2 as an administered therapeutic is therefore limited, anchored mainly in diagnostic use and small mechanistic studies [1,2].

Sources

  1. 1. Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN Drugs in R&D, 2004.
  2. 2. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men The Journal of clinical endocrinology and metabolism, 2005.
  3. 3. Detection of GHRP-2 and GHRP-6 in urine samples from athletes Drug testing and analysis, 2015.
  4. 4. GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1 Life sciences, 2008.

For educational purposes only.

← Back to the encyclopedia